Targeted agent (TA) use at the end of life (EOL).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e19603-e19603
Author(s):  
Meghan Sri Karuturi ◽  
Kimberson Tanco ◽  
Jung Hye Kwon ◽  
Tao Zhang ◽  
Wadih Rhondali ◽  
...  

e19603 Background: Chemotherapy in the last days of life has questionable benefit and has been proposed as an indicator of poor quality of EOL care. The use of TAs at the EOL has not been examined. We determined the proportion and predictors of TA use in the last 30 days of life. Methods: All adult patients in the Houston area who died of advanced cancer between 9/1/2009 and 2/28/2010 while under the care of our institution were included. We collected baseline demographics and data on chemotherapy and TAs. Multivariate logistic regression was used to identify predictors of targeted therapy use. Results: 912 patients were included: average age 63 (range 21-98), female 49%, Caucasian 63%. Within the last 30 and 14 days of life, 117 (13%) and 56 (6%) patients received TAs, respectively, while 148 (16%) and 65 (7%) received chemotherapy. The interval between last TA use and death was 49 (21-106) days. Regimens given in the last 30 days of life included a median of 2 (1-2) chemotherapeutic/targeted agents, and the most common TAs were erlotinib (N=22), bevacizumab (N=19), rituximab (N=9), gemtuzumab (N=9) and temsirolimus (N=8). 43/117 (37%) patients who received TAs within the last 30 days of life had concurrent chemotherapy. In multivariate analysis, younger age and hematologic malignancies were associated with increased TA use (Table). Conclusions: TAs were used as often as chemotherapy at the EOL, particularly among younger patients and those with hematologic malignancies. Use of TAs in the last 30 days of life may have implications for quality of EOL care. [Table: see text]

2012 ◽  
Vol 30 (34_suppl) ◽  
pp. 215-215 ◽  
Author(s):  
David Hui ◽  
Meghan Sri Karuturi ◽  
Kimberson Cochien Tanco ◽  
Jung Hye Kwon ◽  
Sun Hyun Kim ◽  
...  

215 Background: Chemotherapy use at the end of life is considered an indicator of poor quality of care. The use of targeted agent has not been well characterized. In this study, we determined the frequency and predictors of targeted therapy use in the last 30 days of life. Methods: All adult patients residing in the Houston area who died of advanced cancer between September 1, 2009 and February 28, 2010 and had contact with our institution within the last three months of life were included. We collected baseline demographics and data on chemotherapy and targeted agents. Results: 816 patients were included: average age 62 (range 21 to 97), female 48% and White 61%. The median interval between the last treatment and death was 47 (interquartile range 21 to 97) days for targeted agents and 57 (26 to 118) days for chemotherapeutic agents. 116 (14%) patients received targeted agents and 147 (18%) received chemotherapy within the last 30 days of life. 43 (5%) patients received targeted agents had concurrent chemotherapy. The most common targeted agents in the last 30 days of life were erlotinib (n=25), bevacizumab (n=20) and rituximab (n=11). In multivariate analysis, younger age, hematologic, and lung malignancies were associated with increased targeted agent use in the last 30 days of life (Table). Conclusions: Targeted agents were used as often as chemotherapy at the end of life, particularly among younger patients and those with hematologic malignancies. Guidelines on targeted therapy use at the end of life are needed. [Table: see text]


2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e24005-e24005
Author(s):  
Renana Barak ◽  
Einav Zagagi Yohay ◽  
Barliz Waissengrin ◽  
Ido Wolf

e24005 Background: Aggressive end-of-life (EOL) care in cancer patients, especially the administration of chemotherapy, is considered a poor-quality measure, that may divert the treatment course from its' main palliative intent. Decisions taken at EOL are more than evidence-based and often rely on cultural and personal prospects. The universal and free Israeli health care system enables the administration of active treatment without financial or regulatory barriers, even at EOL. Two major advancements in recent years were the implementation of national at-home palliative care services and the approval of targeted and immunotherapies for advanced cancers. We hypothesized that these changes will reduce the use of chemotherapy at EOL. Methods: We sampled consecutive patients treated at a tertiary oncology center who died of advanced cancers between January 2019 to August 2020, and examined the administration of oncologic treatments near EOL. Results: A total of 294 patients were included. Their median age was 67 and 147 were men, 64% (189) of the patients received oncologic treatment during the last month before death, chemotherapy was administered in nearly two-thirds of the cases, 64% (121), followed by immunotherapy (21%, 40), targeted therapy (10%, 19) and a clinical trial (5%, 9). Neither age (P = 0.4), gender (P = 0.9), performance status (P = 0.8), disease duration (P = 0.5), and type of previous oncologic treatment (P = 0.3) were associated with aggressive EOL care. Conclusions: Our data demonstrate that in the absence of any regulatory or financial limitations, an aggressive EOL care may be administered to the majority of patients, regardless of age, performance status or disease duration. Despite increasing use of immunotherapy and targeted therapies and despite its’ toxicity profile and low beneficial effect at this stage, chemotherapy remained the most commonly used type of treatment. These data call for the implementation of educational measures and appropriate universal guidelines, aiming at improving quality of treatment at the EOL, focusing on quality of life rather than the elusive potential of extending life.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 3290-3290 ◽  
Author(s):  
Oreofe O. Odejide ◽  
Angel M. Cronin ◽  
Nolan B. Condron ◽  
Sean A. Fletcher ◽  
Craig Earle ◽  
...  

Abstract Background: Hematologic malignancies have been associated with poor performance on standard measures of quality of end-of-life (EOL) care in oncology (eg, Hui, Cancer, 2014); however, these measures were originally developed primarily for solid tumors, and they may not appropriately address EOL quality issues for patients with blood cancers. We sought to explore hematologic oncologists' perspectives regarding the acceptability of current oncology EOL quality measures, hypothesizing that they would report them to be largely unacceptable. Methods: In 2014, we mailed a 30-item survey to a national sample of hematologic oncologists randomly selected from the American Society of Hematology clinical directory. The survey was developed through focus groups (n=20) and cognitive debriefing (n=5) with hematologists whose practices focus on patients with blood cancers. In the resulting survey, we provided a list of standard EOL quality measures (Earle, JCO, 2003; Keating, Cancer, 2010; Phelps, JAMA, 2009; see table) and two novel hematology-based measures (no red cell transfusions ≤ 7 days before death, and no platelet transfusions ≤ 7 days before death) and asked "Please indicate whether or not you feel each is an acceptable indicator of good quality EOL care for patients with hematologic malignancies." We decided a priori that we would consider a measure to be "highly acceptable" if there were at least 75% agreement among hematologic oncologists on its acceptability. Worrying that they might reject them all, we also asked them to identify three measures they would choose in a scenario where three had to be adopted. Results: We received 349 surveys from 48 states (response rate: 57.3%). Non-responders were not significantly different across known variables (gender and region of practice). Among respondents, median age was 52 years, median time in practice was 25 years, and 43% practiced primarily in tertiary centers. Eighty-seven percent were board-certified in oncology, 81% in hematology, and 71% in both specialties. The table below shows acceptability of the quality measures as rated by respondents. In the exercise where three measures had to be chosen, the one chosen most often was no CPR within 30 days of death (54%), followed by enrollment in hospice >7 days before death (46%). Conclusions: In contrast to our hypothesis, all of the measures we presented were considered acceptable by a substantial proportion of the hematologic oncologists in our national cohort. Moreover, while four of the measures reached our a priori designation of being highly acceptable, the two hematology-focused measures did not meet this same threshold. These data suggest that in hematologic oncology, resources should be directed towards addressing barriers to performance on established EOL quality measures in addition to creating new ones. Figure 1. Figure 1. Disclosures No relevant conflicts of interest to declare.


2008 ◽  
Vol 26 (35) ◽  
pp. 5775-5782 ◽  
Author(s):  
Juan José Lahuerta ◽  
Maria Victoria Mateos ◽  
Joaquin Martínez-López ◽  
Laura Rosiñol ◽  
Anna Sureda ◽  
...  

Purpose Complete response (CR) is considered an important goal in most hematologic malignancies. However, in multiple myeloma (MM), there is no consensus regarding whether immunofixation (IF)-negative CR, IF-positive near-CR (nCR), and partial response (PR) are associated with different survivals. We evaluated the prognostic influence on event-free survival (EFS) and overall survival (OS) of these responses pre- and post-transplantation in newly diagnosed patients with MM. Patients and Methods We analyzed 632 patients from the prospective Grupo Español de Mieloma 2000 protocol who were uniformly treated with vincristine, carmustine, cyclophosphamide, melphalan, and predisone/vincristine, carmustine, adryamcine, and dexamethasone induction followed by high-dose therapy and autologous stem-cell transplantation. Results Post-transplantation response markedly influenced outcomes. Patients achieving CR had significantly longer EFS (median, 61 v 40 months; P < 10−5) and OS (medians not reached; P = .01) versus patients achieving nCR, who likewise had somewhat better outcomes compared with patients achieving PR (median EFS, 34 months, P = .07 v nCR; median OS, 61 months, P = .04). EFS and OS and influence of response were similar among older (age 65 to 70 years) and younger (age < 65 years) patients. Similar findings were observed with pretransplantation response, with trends toward EFS (P = .1; P = .05) and OS (P = .1; P = .07) benefit in patients achieving CR versus nCR and PR, respectively. Post-transplantation response was markedly influenced by pretransplantation response; improvements in response were associated with prolonged survival. Conclusion Quality of response post-transplantation, notably CR, is significantly associated with EFS and OS prolongation in newly diagnosed patients with MM. There were trends toward similar associations with pretransplantation response status.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 1375-1375
Author(s):  
Anthony J. Cannon ◽  
Deborah L. Darrington ◽  
Linda K. Bauer ◽  
James O. Armitage ◽  
Julie M. Vose ◽  
...  

Abstract Abstract 1375 Poster Board I-397 Objectives: There is a critical need to have a better understanding of the role health providers play and the need to develop clinical tools to help clinicians identify patients who after completion of treatment for hematologic malignancies may benefit from a more intense follow-up care. The primary purpose of this study was to examine if number of follow-up providers (FUPs) - single versus multiple, influence healthcare utilization (HCU), quality of life and patient satisfaction at 6 months in a cohort of patients who completed treatment for hematologic malignancies. A secondary purpose was to evaluate characteristics of follow-up care that may identify patients at risk for urgent care or hospitalization within 6 months. Methods: We utilized data from CANCER-CARES, a longitudinal prospective study of 928 patients with various cancers evaluating follow-up care after completing cancer treatment from a university-based hospital. This study was confined to 314 (52%) patients who had leukemia, lymphoma or multiple myeloma with available 6 month follow-up information. The cohort was divided according to the number of FUPs - single versus multiple. FUP is defined as a physician(s) responsible for managing any aspect of patient's health after cancer treatment. Single FUP may consist solely of a university or community oncologist or other physicians, while multiple FUP may be any combination of the above. Outcomes evaluated included healthcare utilization (HCU) - defined as an emergency room visit or hospitalization within 6 mos, quality of life (SF-12) and patient satisfaction (PSQ-18). Characteristics of follow-up care assocatied with HCU were determined using multivariate logistic regression. Factors determined to be predictive of HCU were assigned one point each. The summated score was used to represent the Follow-up Index Score (FUIS). We used the median FUIS of ≤ 2 to dichotomize the cohort to low vs high scores. The association of the FUIS according to single or multiple FUP with HCU was evaluated using multivariate logistic regression to adjust for patient characteristics. Results: Of the 314 patients, 214 (68%) sought follow-up care with a single FUP (80% remained with university providers, 20% moved back to community providers), while 100 (32%) sought follow-up care with multiple FUPs. Patients seen by single FUP were more likely to be older (median 59y vs 55y), live closer to their FUP (median 60 mi vs 150 mi), less likely to have prescription drug insurance (85% vs 94%), and were less likely to have undergone stem-cell transplantation. Patients seen by single FUP chose their physician more because of preference and quality of care than because of proximity, and were seen less frequently by their FUP as compared to the multiple FUPs. In addition, patients of single providers were seen shorter on their follow-up visits and were less likely to call their FUP with health-related questions. Five patterns of follow-up care were associated with HCU within 6 mos: 1) consult made for cancer-related problems, 2) consult made for other medical problems, 3) referral to another specialist, 4) call made to FUP for medical questions, and 5) ancillary procedures performed (ct, x-ray, ultrasound). In the multivariate analysis, patients seen by single or multiple FUP did not differ in HCU, quality of life and patient satisfaction. However, patients who were seen either by a single or multiple FUP and with low FUIS had significantly lower odds of HCU compared with single FUP with high FUIS [OR 0.11 (95%CI 0.05-0.25), p<0.001; OR 0.26 (95% CI 0.09-0.71), p<0.001) respectively. Patients seen by multiple FUP and have low FUIS also had lower odds of HCU compared with patients with multiple FUP and have high FUIS (OR 0.30, 95% CI 0.10-0.85, p<0.001). We failed to detect differences between patients seen by single or multiple FUPs with low FUIS. No differences in quality of life or patient satisfaction were noted. Conclusion: In summary, patients with hematologic malignancies do not differ between patients who sought follow-up care from single or multiple FUP on HCU, quality of life or patient satisfaction. However, the FUIS shows potential to identify patients who may benefit from an intensive follow-up care plan geared towards preventing hospitalization because it demonstrated that high FUIS scores were associated with increased HCU within a 6 mo. period. The utility of the FUIS in predicting HCU between 6 and 12 months and in different types of malignancies should also be evaluated. Disclosures: No relevant conflicts of interest to declare.


2016 ◽  
Vol 19 (2) ◽  
pp. 198-205 ◽  
Author(s):  
José Miguel Rivera-Caravaca ◽  
Inmaculada Viedma-Viedma ◽  
Vanessa Roldán

Introduction: Treatment of venous thromboembolism (VTE) is classically based on oral vitamin K antagonists (VKAs). Due to the disadvantages and side effects of these drugs, monitoring the quality of anticoagulation by assessing time within therapeutic range (TTR) is recommended. Variables altering the TTR in patients with VTE are yet to be determined. The aim of this study was to analyze the quality of anticoagulation in patients with VTE treated with VKAs and to identify factors associated with poor-quality anticoagulation. Methods: A retrospective observational study was performed in a cohort of 94 patients diagnosed with VTE undergoing treatment with VKAs. The TTR at 6 months was analyzed by the Rosendaal method. Univariate and a multivariate logistic regression analyses were performed to unravel factors that increase risk of poor-quality anticoagulation. Results: The TTR at 6 months in this cohort was 60.5%; 54 patients had a TTR < 65%. In the univariate analysis, female sex, age ≥ 65 years, and renal impairment were significantly associated with poor-quality anticoagulation. However, in the multivariate logistic regression model, only renal impairment was independently associated with poor-quality anticoagulation (odds ratio = 3.31, 95% confidence interval [1.049, 10.486], p = .041). Discussion: The average quality of anticoagulation was 60.5%, and a high percentage of patients had a quality of anticoagulation below recommended levels. Study findings indicate that renal impairment is an independent risk factor for poor-quality anticoagulation in patients with VTE treated with VKAs.


2011 ◽  
Vol 38 (12) ◽  
pp. 2608-2615 ◽  
Author(s):  
DEREK L. MATTEY ◽  
SARAH R. DAWSON ◽  
EMMA L. HEALEY ◽  
JONATHAN C. PACKHAM

Objective.To investigate the relationship between smoking and disease activity, pain, function, and quality of life in patients with ankylosing spondylitis (AS).Methods.Patients with AS (n = 612) from areas across the United Kingdom took part in a cross-sectional postal survey. Patient-reported outcome measures including the Bath AS Disease Activity Index, the Bath AS Functional Index (BASFI), a numerical rating scale (NRS) of pain, the AS quality of life questionnaire (ASQoL), and the evaluation of AS quality of life measures (EASi-QoL) were analyzed in terms of smoking status and relationship with pack-year history. The influence of potential confounding factors [age, sex, disease duration, and social deprivation (Townsend Index)] were tested in multivariate logistic regression analyses.Results.Median scores of BASFI, pain NRS, ASQoL, and the 4 EASi-QoL domains were all higher in the group that had ever smoked compared to those who had never smoked (p < 0.0001, p = 0.04, p = 0.003, p < 0.02, respectively). In stepwise multivariate logistic regression analyses, high disease activity and more severe pain were associated primarily with current smoking, disease duration, and Townsend Index score, while decreased function and poor quality of life measures were associated more closely with increasing pack-year history, disease duration, and Townsend Index score. These associations were independent of age and sex.Conclusion.Smoking has a dose-dependent relationship with measures of disease severity in AS. The association with increased disease activity, decreased function, and poor quality of life in smokers was independent of age, sex, deprivation level, and disease duration.


2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e21502-e21502
Author(s):  
Elisa De Carlo ◽  
Lorenzo Gerratana ◽  
Marika Cinausero ◽  
Maria Grazia Vitale ◽  
Vanessa Buoro ◽  
...  

e21502 Background: Limited data are available on how the setting and timing of palliative care (PC) referral can affect end-of-life (EoL) care and survival in cancer patients (pts). The aim of our study was to evaluate the impact of PC referral (hospice and/or home-care services) versus family physician care (FP-C), in terms of both EoL quality of care and survival in cancer pts. Methods: The study included 337 cancer pts who died between January 2015 and February 2016. We retrieved data on type of EoL care and on poor quality of care indicators in the last 30 days of life. Palliative Care Survival (PCS) was defined as the interval between timing of PC referral and death. The survival after treatment (Treatment-Free Survival, TFS) was defined as the interval between the last administration of anticancer therapy and death. Results: FP-C court included 89 pts and PC services court 248 pts. The 248 PC pts were divided in three groups: 99 assisted by both PC services, 58 only by home-care and 91 only by hospice care. The median PCS was 24 days. TFS was significantly longer for the three groups assisted by PC (105, 95, and 82 days respectively) than for that assisted only by FP-C (49 days, p < 0.0001). Compared to PC services, FP-C was associated with higher frequency of poor quality of care indicators, such as emergency room visits (p < 0.0001), hospitalizations (p < 0.0001), hospital death (p < 0.0001) and chemotherapy administration (p < 0.0001). In addition, earlier PC referral (30-60 and > 60 days before death) versus late referral ( < 30 days before death) was associated with a lower frequency of poor quality indicators. Variables such as age, sex and primary tumor were not associated with a different quality of care. Conclusions: Pts referred to PC services, compared to pts referred only to FP-C, had improved EoL survival and quality of care. A better definition of PC referral timing can affect the quality of EoL care in cancer pts.


2020 ◽  
pp. 34-36
Author(s):  
M. A. Pokhaznikova ◽  
E. A. Andreeva ◽  
O. Yu. Kuznetsova

The article discusses the experience of teaching and conducting spirometry of general practitioners as part of the RESPECT study (RESearch on the PrEvalence and the diagnosis of COPD and its Tobacco-related aetiology). A total of 33 trained in spirometry general practitioners performed a study of 3119 patients. Quality criteria met 84.1% of spirometric studies. The analysis of the most common mistakes made by doctors during the forced expiratory maneuver is included. The most frequent errors were expiration exhalation of less than 6s (54%), non-maximal effort throughout the test and lack of reproducibility (11.3%). Independent predictors of poor spirogram quality were male gender, obstruction (FEV1 /FVC<0.7), and the center where the study was performed. The number of good-quality spirograms ranged from 96.1% (95% CI 83.2–110.4) to 59.8% (95% CI 49.6–71.4) depending on the center. Subsequently, an analysis of the reasons behind the poor quality of research in individual centers was conducted and the identified shortcomings were eliminated. The poor quality of the spirograms was associated either with the errors of the doctors who undertook the study or with the technical malfunctions of the spirometer.


Sign in / Sign up

Export Citation Format

Share Document